MSB 2022 - The road to commercialisation, page-603

Mate are you paying attention
1 You stated there should have been an RCT with SOC as the placebo
2 I pointed out that no parent would enrol in the trial as the placebo was a certain death sentence
3 Then the last post is obviously there is a certain SOC which they must be getting

Let’s start again …Grade 3-4 aGvHD has a mortality rate at present SOC of 85-90% at 180 days
With Rem-l the mortality rate at 1 year is about 30-35% at over 1 year
The question you have to ask is it ethical to have a placebo with no cross over for grade 3-4 disease which will mean certain death if you get the short straw